Volume 19 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(8): 1306-1309
JIANG Yi-ling, ZHANG Chuan-ling, CHEN Cheng, YU Hong-jin, LI Wei-na, FANG Jing, FANG Yong. Observation of curative effect of bevacizumab combined with targeted treatment of EGFR mutant lung cancer[J]. Chinese Journal of General Practice, 2021, 19(8): 1306-1309. doi: 10.16766/j.cnki.issn.1674-4152.002047
Citation: JIANG Yi-ling, ZHANG Chuan-ling, CHEN Cheng, YU Hong-jin, LI Wei-na, FANG Jing, FANG Yong. Observation of curative effect of bevacizumab combined with targeted treatment of EGFR mutant lung cancer[J]. Chinese Journal of General Practice, 2021, 19(8): 1306-1309. doi: 10.16766/j.cnki.issn.1674-4152.002047
shu

Observation of curative effect of bevacizumab combined with targeted treatment of EGFR mutant lung cancer

doi: 10.16766/j.cnki.issn.1674-4152.002047
  • 1.

    Department of Oncology, Zhejiang Xiaoshan Hospital, Hangzhou, Zhejiang 311201, China

Funds:

 2019RC256

  • Received Date: 2021-09-25
    Available Online: 2022-02-16
    Abstract
  •   Objective  To investigate the effect of bevacizumab combined with targeted therapy on the short- and long-term prognosis, immune status, and side effects of patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), in order to provide reference for the choice of clinical treatment.   Methods   A total of 80 EGFR-mutant NSCLC patients who were diagnosed and treated in our hospital from September 2017 to September 2018 were selected and divided into control group and observation group according to the random number table method, with 40 cases in each group. The control group was treated with icotinib hydrochloride tablets, and the observation group was treated with bevacizumab combined with icotinib hydrochloride tablets. The clinical efficacy, tumor marker levels, and immune index levels were compared between the two groups of patients, and the survival and toxicity of the two groups were compared.   Results   The disease control rate (DCR) of the observation group was significantly higher than that of the control group (P < 0.05). After treatment, the levels of vascular endothelial growth factor (VEGF), carbohydrate antigen 125 (CA125), and cytokeratin 19 fragment (CYFRA21-1) in the two groups were significantly lower than those before treatment, and the observation group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of CD3+, CD4+/CD8+ in the two groups were significantly higher than those before treatment, and the observation group were significantly higher than those in the control group (P < 0.05). The survival of patients in the observation group was better than that of the control group (P < 0.05). The total incidence of side effects in the observation group was significantly lower than that in the control group (P < 0.05).   Conclusion   Bevacizumab combined with icotinib hydrochloride in the treatment of EGFR mutant NSCLC patients has a significant effect, which can effectively inhibit the proliferation of tumor cells, reduce the tumor volume, improve the body's immune function, and improve the survival rate of patients.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    王聪慧. 中医药联合吉非替尼治疗中晚期非小细胞肺癌有效性和安全性的Meta分析及试验序贯分析[J]. 中药材, 2019, 42(8): 1938-1946. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYCA201908047.htm
    [2]
    张双美, 王斌, 陈怡, 等. 长链非编码RNA PVT1对非小细胞肺癌细胞增殖和迁移能力的影响及其机制研究[J]. 中华全科医学, 2019, 17(6): 897-901. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201906004.htm
    [3]
    杨双宁, 李楠, 王丽萍, 等. 埃克替尼联合化疗治疗EGFR突变型晚期非小细胞肺癌的临床效果[J]. 郑州大学学报(医学版), 2020, 55(1): 53-56. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYK202001013.htm
    [4]
    潘钦石, 胡丽娟, 林晓梅, 等. 盐酸埃克替尼对肺癌A549细胞PI3K/AKT、HIF-1α信号通路的影响[J]. 中华全科医学, 2016, 14(5): 705-708. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201605004.htm
    [5]
    陶虹, 郭丽丽, 吴洪波, 等. 贝伐珠单抗联合化疗对复治晚期非鳞非小细胞肺癌患者的疗效及预后分析[J]. 中国肿瘤临床, 2018, 45(10): 503-507. doi: 10.3969/j.issn.1000-8179.2018.10.402
    [6]
    王慧芳, 宋利刚. 贝伐珠单抗注射液辅助规范化疗治疗非小细胞肺癌的临床效果[J]. 中国老年学杂志, 2018, 38(21): 5193-5195. doi: 10.3969/j.issn.1005-9202.2018.21.030
    [7]
    史云舒, 李盼华, 李班班, 等. EGFR基因少见突变型非小细胞肺癌的临床特征及应用EGFR-TKIs治疗效果评价[J]. 中国肺癌杂志, 2019, 22(5): 299-305. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201905007.htm
    [8]
    郭海荣, 胡继德. TP化疗方案联合贝伐珠单抗治疗晚期NSCLC的效果观察[J]. 实用中西医结合临床, 2020, 20(10): 80-81. https://www.cnki.com.cn/Article/CJFDTOTAL-SZXL202010042.htm
    [9]
    TANAKA K, NOSAKI K, OTSUBO K, et al. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-nave patients with non-small cell lung cancer harboring EGFR mutations[J]. Oncotarget, 2017, 8(40): 68123-68130. doi: 10.18632/oncotarget.19243
    [10]
    赵秋红, 闫春良, 任冠军. 盐酸埃克替尼对中晚期表皮生长因子受体突变型非小细胞肺癌疗效及免疫指标的影响[J]. 癌症进展, 2020, 18(15): 1589-1592. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202015021.htm
    [11]
    昂冰, 武乐, 周彩云. 贝伐珠单抗联合顺铂治疗肺癌恶性胸水的临床疗效[J]. 中国肿瘤生物治疗杂志, 2018, 25(11): 1176-1179. doi: 10.3872/j.issn.1007-385X.2018.11.016
    [12]
    FEI Q, XINGSHENG H, YUTAO L, et al. First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China[J]. Chinese J Cancer Res, 2019, 31(5): 749-758. doi: 10.21147/j.issn.1000-9604.2019.05.05
    [13]
    陈惠, 王汉萍, 张力, 等. 盐酸埃克替尼一线治疗晚期非小细胞肺癌的疗效与安全性[J]. 中华内科杂志, 2017, 56(1): 39-43. doi: 10.3760/cma.j.issn.0578-1426.2017.01.010
    [14]
    储天晴, 陈姬华, 韩宝惠. 贝伐珠单抗治疗晚期非小细胞肺癌的研究进展[J]. 中华肿瘤杂志, 2018, 40(10): 793-800. doi: 10.3760/cma.j.issn.0253-3766.2018.10.013
    [15]
    樊慧杰, 袁静, 吴晶晶, 等. VEGFR2多态性对贝伐珠单抗联合化疗一线治疗晚期非小细胞肺癌患者效果及安全性的影响[J]. 中华医学杂志, 2019, 99(2): 99-104. doi: 10.3760/cma.j.issn.0376-2491.2019.02.005
    [16]
    单艳, 李志刚, 姬卫国, 等. VEGFR2基因V297I位点对贝伐珠单抗联合化疗一线治疗晚期非小细胞肺癌患者临床疗效的影响[J]. 中国肿瘤生物治疗杂志, 2019, 26(1): 67-72. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW201901011.htm
    [17]
    邢若, 王鹏, 刘玉豪. 贝伐珠单抗辅助常规化疗治疗非小细胞肺癌的临床研究[J]. 中国临床药理学杂志, 2019, 35(1): 17-19. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201901005.htm
    [18]
    蒋友国, 王韬渊, 刘军涛, 等. 贝伐珠单抗联合埃克替尼治疗中晚期非小细胞肺癌的临床研究[J]. 现代药物与临床, 2018, 33(12): 3259-3263. https://www.cnki.com.cn/Article/CJFDTOTAL-GWZW201812040.htm
    [19]
    MATEU-JIMENEZ M, CURULL V, PIJUAN L, et al. Systemic and tumor Th1 and Th2 inflammatory profile and macrophages in lung cancer: influence of underlying chronic respiratory disease[J]. J Thorac Oncol, 2017, 12(2): 235-248. doi: 10.1016/j.jtho.2016.09.137
    [20]
    艾斌, 杨轶璠. 贝伐珠单抗在晚期非小细胞肺癌一线治疗中的研究进展[J]. 中国肺癌杂志, 2020, 23(7): 626-630. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ202007015.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (154) PDF downloads(6) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return